StockCall Review on Dynavax and GlaxoSmithKline: Pharma Stocks Bet on Drug
LONDON, February 12, 2013
LONDON, February 12, 2013 /PRNewswire/ --
Any drug company's stock price hinges on the performance of its drugs. One of
the very first steps involved in marketing a drug is getting the approval of
FDA. Dynavax Technologies Corporation (NASDAQ: DVAX) is one such company that
pointed out that the point recently. The stock plummeted when its drug
candidate received poor reviews. However, the same Hepatitis B drug is now
waiting for the final approval and the FDA's decision will have a major impact
on the future direction taken by Dynavax Technologies stock. Similarly,
GlaxoSmithKline Plc (NYSE: GSK) is also awaiting FDA's decision for its major
drug candidates. The drug industry is also dealing with problems like patent
expiries and falling revenues as GlaxoSmithKline posted weak results. The drug
industry is expected to see consolidation this year as major companies may
acquire smaller biotech firms to plug the losses caused by expired patents.
StockCall analysts initiated preliminary technical research on Dynavax and
GlaxoSmithKline. These free reports are accessible by signing today at
GlaxoSmithKline Posts Q4 Results
GlaxoSmithKline Plc reported lower income for its fourth quarter of the year.
The company earned 57 cents per share, down from 90 cents per share it had
earned a year earlier. Its revenue for the quarter stood at $11 billion.
Overall, the results were lower-than-expected. However, all is not bad when it
comes to GlaxoSmithKline. The company sports healthy margins. It is also doing
well on the growth front as it finalized the acquisition of Human Genome
Sciences. With this acquisition, the company also gained the access to
Benlysta, which is used to treat Lupus. Register now to download the free
research on GlaxoSmithKline at http://www.StockCall.com/GSK021213.pdf
GlaxoSmithKline stock increased 1.72 percent in the past 12 months and the
company is taking steps to improve its stock price performance. It is looking
to expand its footprints in emerging markets. The company recently inked a new
joint venture in India for developing a multi-use vaccine for ailments such as
Hepatitis B. GlaxoSmithKline also has strong pipeline as it expects to get
reviews for six of its drugs in 2013. These drugs may prove to be a major
catalyst for GlaxoSmithKline stock, as and when they receive approval.
Improvement in global and European economy is also likely to have positive
impact on the stock. Apart from growth prospects, the stock also offers
mouthwatering dividend yield of 5.10 percent.
Dynavax Technologies Waits for FDA Decision
Dynavax Technologies Corporation is waiting for FDA's decision for its
Hepatitis B drug Heplisav. The decision is due out on February 24^th. If
approved, the drug may open up a lucrative market for Dynavax Technologies.
However, there are certain apprehensions about the drug receiving
unconditional approval. The free technical analysis on Dynavax Technologies is
available by signing up at http://www.StockCall.com/DVAX021213.pdf
Dynavax Technologies was thoroughly beaten down late last year, after getting
negative safety vote for Heplisav. However, since then the stock has recovered
nicely. It is currently trading slightly above its 20-day moving average price
of $3.26, showing neutral trend. However, it is expected to breakout, if its
Hepatitis B drug receives the approval. There are quite high chances of the
drug receiving approval and the stock looks attractive at the moment.
StockCall.com is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at http://www.stockcall.com
Contact: William T. Knight, Email: email@example.com, Contact Number:
+1-646-396-9857 (9:00 am EST - 01:30 pm EST)
Press spacebar to pause and continue. Press esc to stop.